Cleopatra, DESTINY-Breast09 & What Comes Next – Drs. Bill Gradishar, Tarah Ballinger, & Megan Kruse

For more than a decade, the Cleopatra regimen transformed outcomes in HER2-positive metastatic breast cancer — delivering landmark overall survival gains and redefining long-term disease control.

Recorded at SABCS, this expert roundtable features Dr. Bill Gradishar, Dr. Tarah Ballinger, and Dr. Megan Kruse as they examine how the HER2 landscape is evolving in the era of antibody–drug conjugates.

The discussion explores the real-world impact of DESTINY-Breast09, the role of trastuzumab deruxtecan (T-DXd) in the first-line setting, and how clinicians are balancing efficacy, toxicity, and quality of life. From induction vs maintenance strategies to emerging data from PATINA and HER2CLIMB-05, this conversation highlights the nuance required in modern HER2+ decision-making.

🎧 A must-watch conversation on progress, uncertainty, and shared decision-making in HER2-positive metastatic breast cancer.